Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

FDA Rebukes Egalet's Reliance On OxyContin Postmarketing Data

Executive Summary

Arymo ER sponsor's consultants said Purdue's postmarketing data on its reformulated oxycodone establish a link between abuse-deterrent properties and reduced real-world abuse, but FDA says it disagreed with the conclusion in the context of an OxyContin labeling supplement.

Advertisement

Related Content

Abuse-Deterrent Opioids: Postmarketing Data Eyed As Development ‘Anchor’
Egalet's Arymo ER Opioid Has Questionable Oral Abuse-Deterrent Effect
Purdue's Pain And No Gain: More Analysis Of OxyContin Postmarket Studies Needed

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS118914

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel